Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates.
Haddox CL, Nathenson MJ, Mazzola E, Lin JR, Baginska J, Nau A, Weirather JL, Choy E, Marino-Enriquez A, Morgan JA, Cote GM, Merriam P, Wagner AJ, Sorger PK, Santagata S, George S. Haddox CL, et al. Among authors: nathenson mj. Clin Cancer Res. 2024 Apr 1;30(7):1281-1292. doi: 10.1158/1078-0432.CCR-23-2250. Clin Cancer Res. 2024. PMID: 38236580 Free PMC article. Clinical Trial.
A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.
Cote GM, Choy E, Chen T, Marino-Enriquez A, Morgan J, Merriam P, Thornton K, Wagner AJ, Nathenson MJ, Demetri G, George S. Cote GM, et al. Among authors: nathenson mj. Eur J Cancer. 2020 Feb;126:21-32. doi: 10.1016/j.ejca.2019.10.021. Epub 2019 Dec 31. Eur J Cancer. 2020. PMID: 31896519 Clinical Trial.
Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1.
Hemming ML, Nathenson MJ, Lin JR, Mei S, Du Z, Malik K, Marino-Enriquez A, Jagannathan JP, Sorger PK, Bertagnolli M, Sicinska E, Demetri GD, Santagata S. Hemming ML, et al. Among authors: nathenson mj. JCO Precis Oncol. 2020;4:79-90. doi: 10.1200/po.19.00287. Epub 2020 Feb 14. JCO Precis Oncol. 2020. PMID: 32133433 Free PMC article. No abstract available.
Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study.
Nathenson MJ, Hu J, Ratan R, Somaiah N, Hsu R, DeMaria PJ, Catoe HW, Pang A, Subhawong TK, Amini B, Sweet K, Feister K, Malik K, Jagannathan J, Braschi-Amirfarzan M, Sheren J, Caldas Y, Moreno Tellez C, Rosenberg AE, Lazar AJ, Maki RG, Benedetto P, Cohen J, Trent JC, Ravi V, Patel S, Wilky BA. Nathenson MJ, et al. Clin Cancer Res. 2022 Sep 15;28(18):4092-4104. doi: 10.1158/1078-0432.CCR-21-4504. Clin Cancer Res. 2022. PMID: 35180772 Free PMC article.
The immune microenvironment of uterine adenosarcomas.
Ali AMR, Tsai JW, Leung CH, Lin H, Ravi V, Conley AP, Lazar AJ, Wang WL, Nathenson MJ. Ali AMR, et al. Among authors: nathenson mj. Clin Sarcoma Res. 2020 Mar 28;10:5. doi: 10.1186/s13569-020-0127-0. eCollection 2020. Clin Sarcoma Res. 2020. PMID: 32231779 Free PMC article.
A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl).
Palmerini E, Gambarotti M, Italiano A, Nathenson MJ, Ratan R, Dileo P, Provenzano S, Jones RL, DuBois SG, Martin-Broto J, de Alava E, Baldi GG, Grignani G, Ferraresi V, Brunello A, Paoluzzi L, Bertulli R, Hindi N, Montemurro M, Rothermundt C, Cocchi S, Salguero-Aranda C, Donati D, Martin JD, Abdelhamid Ahmed AH, Mazzocca A, Carretta E, Cesari M, Pierini M, Righi A, Sbaraglia M, Laginestra MA, Scotlandi K, Dei Tos AP, Ibrahim T, Stacchiotti S, Vincenzi B. Palmerini E, et al. Among authors: nathenson mj. Eur J Cancer. 2023 Apr;183:11-23. doi: 10.1016/j.ejca.2023.01.003. Epub 2023 Jan 18. Eur J Cancer. 2023. PMID: 36791667
22 results